Related Experiment Video
Updated: Jun 26, 2026
06:19
Intracameral Injection in Rats with Low Risk of Adverse Effects
Published on: May 31, 2024
Intraocular sustained-release delivery systems for triamcinolone acetonide
Saffar Mansoor1, Baruch D Kuppermann, M Cristina Kenney
1Department of Ophthalmology, School of Medicine, University of California Irvine, Irvine, California, USA.
Pharmaceutical Research
|February 3, 2009
Summary
Researchers are developing sustained-release systems for triamcinolone acetonide (TA) eye injections to treat chronic retinal diseases like AMD. This aims to reduce complications from repeated intravitreal injections.
Area of Science:
- Ophthalmology
- Retinal Diseases
- Drug Delivery Systems
Background:
- Triamcinolone acetonide (TA) injections are increasingly used for ocular diseases.
- Macular diseases like diabetic retinopathy, venous occlusive diseases, ocular inflammation, and age-related macular degeneration (AMD) are common and challenging to treat.
- Chronic retinal diseases often require repeated intraocular TA injections, increasing complication risks.
Purpose of the Study:
- To review and compare emerging sustained-release (SR) devices and injectable systems for TA.
- To address the need for reduced intravitreal injection frequency.
- To maintain therapeutic TA levels for longer durations.
Main Methods:
- Review of current research and development in sustained-release TA delivery systems.
- Comparison of various implantable devices and injectable formulations.
- Analysis of potential benefits and challenges of different approaches.
Main Results:
- No commercial sustained-release TA product is currently available.
- Multiple innovative implantable devices and injectable systems are under development.
- These systems aim to provide prolonged TA release and reduce injection frequency.
Conclusions:
- Sustained-release formulations are crucial for improving TA treatment efficacy and safety in chronic retinal diseases.
- Further development is needed to bring these advanced drug delivery systems to the commercial market.
- Successful development could significantly reduce complications associated with repeated intravitreal injections.
Related Concept Videos
01:23Ophthalmic Drug Delivery Systems
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
01:22Drug Delivery: Miscellaneous Routes
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
01:21Intrauterine Drug Delivery Systems
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
01:11Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.